Aprepitant
Indications
Information about indications was extracted from the indications and usage sections of the labels.
| Side effects: | 97 |
| Source: | Medsafe |
|---|
| Side effects: | 115 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 88 |
| Source: | EMA |
|---|
| Side effects: | 122 |
| Source: | medicines.org.au |
|---|
| Side effects: | 81 |
| Source: | FDA |
|---|
| Side effects: | 81 |
| Source: | FDA |
|---|
| Side effects: | 119 |
| Source: | FDA |
|---|
| Side effects: | 124 |
| Source: | Health Canada |
|---|
| Side effects: | 128 |
| Source: | Health Canada |
|---|
| Side effects: | 142 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 143 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 144 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 143 |
| Source: | FDA |
|---|
| Side effects: | 144 |
| Source: | FDA |
|---|
| Side effects: | 144 |
| Source: | FDA |
|---|
Color scheme:
standard – alternative
|
|
|
100%
|
|
|
|
75%
|
|
|
|
50%
|
|
|
|
10%
|
|
|
|
frequent (1% to 100%)
|
|
|
|
infrequent (0.1% to 1%)
|
|
|
|
rare (<0.1%)
|
|
|
|
postmarketing
|
|
|
|
0%
|
|
|
|
no frequency information
|
|
|
|
not found on label
|